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Assessing dystrophies and other muscle 
diseases at the nanometer scale by atomic 
force microscopy
Aim: Atomic force microscopy nanoindentation of myofibers was used to assess and 
quantitatively diagnose muscular dystrophies from human patients. Materials & 
methods: Myofibers were probed from fresh or frozen muscle biopsies from human 
dystrophic patients and healthy volunteers, as well as mice models, and Young’s 
modulus stiffness values were determined. Results: Fibers displaying abnormally low 
mechanical stability were detected in biopsies from patients affected by 11 distinct 
muscle diseases, and Young’s modulus values were commensurate to the severity 
of the disease. Abnormal myofiber resistance was also observed from consulting 
patients whose muscle condition could not be detected or unambiguously diagnosed 
otherwise. Discussion & conclusion: This study provides a proof-of-concept that atomic 
force microscopy yields a quantitative read-out of human muscle function from clinical 
biopsies, and that it may thereby complement current muscular dystrophy diagnosis.
KEYWORDS: atomic force microscopy • diagnosis • muscular dystrophy • nanoindentation
Muscle dystrophies (MDs) are hereditary 
muscle diseases that cause progressive muscle 
weakness. MDs often result from various 
mutated genes that encode distinct muscle-
specific proteins, with the consequence of a 
degeneration of myofibers and progressive 
muscle fibrosis. The most severe forms are 
Duchenne MD (DMD) and Becker MD 
(BMD), in which the dys trophin protein 
is absent or truncated to various degrees. 
Dystro phin provides a mechanical link 
between the fiber’s inner cytoskeleton and 
the extra cellular matrix. The lack of dystro-
phin has been associated with more frequent 
membrane ruptures during muscle contrac-
tion, a gradual exhaustion of the muscle stem 
cells that act to regenerate damaged fibers 
and eventual muscle fiber loss [1,2]. However, 
muscle degeneration has been associated with 
a wider range of clinically and pathologically 
recognized MDs, and a number of these could 
be associated with the ab normal function of 
various other muscle proteins [3–5]. While the 
loss or the aberrant structure of myofibers can 
be assessed by histological studies of muscle 
biopsies, characterization of these MDs often 
requires the molecular identification of the 
responsible gene or protein. However, a pre-
symptomatic quantitative functional assay 
of muscle fibers is currently lacking for such 
MDs and other similar  diseases. 
Atomic force microscopy (AFM) was first 
applied in biology as a surface imaging tech-
nique, but has more recently been applied 
to study the mechanical properties of living 
cell membranes by nanoindentation [6–8]. 
The stiffness measured for isolated cultured 
cells ranges from 0.1 to 100 kPa, depending 
on cell type, sample preparation, indentation 
depth and calculation model [6,9]. The domi-
nance of the cytoskeleton in determining cell 
stiffness has been shown by different stud-
ies. For instance, the depolymerization of the 
cytoskeleton F-actin by cytochalasin D led to 
a reduction of fibroblast cell stiffness, show-
ing that the F-actin network plays a crucial 
role in maintaining the mechanical resistance 
of the cell membranes [10]. Microtubules may 
also contribute to cellular stiffness when their 
depolymerization leads to rearrangement 
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or disassembly of the other filament types. However, 
most studies involving microtubule de polymerization 
reported little effect on cell membrane mechanical 
resistance [11,12].
The pathological loss of the cell membrane’s anchor-
age to the inner cytoskeletal network, or an abnormal 
constitution of the extra cellular matrix or cytoskeleton 
have also been shown to result in a lower mechanical 
resistance to sub cellular nanoindentation as probed by 
AFM [13]. For instance, assays of metastatic or non-
metastatic cancer cell lines have revealed a correlation 
between the ability of the cell membrane to deform 
at the nanometer scale with its reduced association to 
the extracellular matrix and ability to invade tissues to 
form metastasis [14–16].
The AFM approach was also shown to provide a 
reliable and sensitive method to assay muscle function 
from fresh muscles explanted from mice at a single 
muscle fiber resolution [17]. In this assay, the sarco-
lemmal membrane of individual muscle fibers were 
probed by nano indentation using the AFM cantilever 
tip and the force needed to reach a specific indentation 
depth was recorded. Assays of dystrophic mouse mus-
cles indicated reduced resistance to de formation com-
pared with healthy muscles, as expected from the lack 
of the dystrophin- mediated physical link to the cyto-
skeleton. Dystrophic muscles treated with viral vectors 
to restore dystrophin expression showed full correction 
of the resistance to deformation in nearly all of the 
muscle fibers. This indicated that AFM truly probed 
the myofiber’s elastic properties as determined by dys-
trophin rather than later muscle degeneration events, 
and that it can provide a quantitative assessment of 
the efficacy of gene-based therapeutic approaches and 
muscle  function in animal models.
In this study, the authors wished to determine if 
AFM may be applied to human frozen biopsies as 
available at clinical diagnostic centers, and whether it 
can be used to detect alterations of myofiber resistance 
in the context of various other human muscular dys-
trophies and myo pathies. The findings from this study 
indicate that the AFM approach is a sensitive method 
to assess human muscles, and that biopsies from DMD 
and BMD patients can be distinguished from those 
of matched healthy individuals. Interestingly, AFM 
also allowed the detection of muscle fiber anomalies 
in biopsies corresponding to various other muscle 
diseases, including from patients whose muscle weak-
nesses could not be attributed to a known molecular 
or genetic defect. Overall, the authors conclude that 
AFM may provide a useful method to complement 
current diagnosis tools of known or un characterized 
human muscle diseases, in research and in a clinical 
context.
Materials & methods
Biopsy preparations
This study was reviewed and approved by the ethical 
institutional review board. All muscle biopsies from 
diagnosed and consulting patients had been previously 
isolated and frozen for routine diagnosis purposes at 
the Lausanne University Hospital, Switzerland, except 
for those from DMD patients and control paravertebral 
muscle biopsies, which were collected and kindly pro-
vided by the Myology Institute in Paris, France. Muscle 
biopsies from three DMD boys (14, 14 and 15 years old) 
and two healthy boys (11 and 16 years old) were avail-
able. Biopsies had been snap frozen in liquid nitrogen or 
in liquid nitrogen-cooled isopentane, as performed for 
molecular analysis or histology purposes, respectively. 
Biopsies from healthy control patients undergoing 
hip prosthesis surgery were obtained under informed 
consent. Healthy patient biopsies were divided into 
three equal samples of approximately 0.7 cm3, a size 
comparable to that of surgical biopsies obtained from 
dystrophic patients. One sample was placed in DMEM 
and kept on ice directly following the surgical removal, 
and the elastic properties of individual myofibers were 
probed using AFM within 8 h of surgical removal with-
out a freezing procedure. Other human biopsies were 
frozen either by direct immersion in liquid nitrogen 
or in liquid nitrogen-cooled isopentane, as performed 
in clinical institutions. Mouse muscles were frozen by 
cooling at -80°C after immersion in DMEM supple-
mented with 10% dimethylsulfoxide. Frozen samples 
were stored in liquid nitrogen until being thawed and 
processed for AFM assays. 
AFM assays
Where applicable, frozen human muscle biopsies were 
allowed to thaw at room temperature for 1 h before 
processing for the AFM assay. Human muscle section-
ing was performed parallel to the myofibers in a rat 
brain slicer matrix (Plastics One, VA, USA) with a 
spacer width of 1 mm to yield slices of uniform thick-
ness. In order to preserve myofiber integrity, muscle 
slices were immediately placed in DMEM and chilled 
on ice until they were measured by AFM. Muscle slices 
were immobilized with muscle fibers lying flat on the 
AFM sample support (Figure 1A). Mouse tibialis ante-
rior (TA) samples were prepared similarly, as  previously 
described [17].
The AFM measurements were performed using a 
device XE-120 (Park Systems, Suwon, Korea) equipped 
with the ‘liquid cell’ setup. The uncoated silicon nitride 
cantilevers (MLCT-AUHW, Veeco, NY, USA) were 
characterized by a tip radius of 50 nm, open angle of 35° 
and nominal cantilever spring constant of 0.01 N/m. 
The force curves – that is, the dependence between the 
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cantilever deflection (proportional to the load force) and 
the distance between the probing tip and sample posi-
tion were recorded at the approach speed of 7 µm/s and 
the Z-range equaled 10 µm. Each tissue section from 
a given patient was divided into two slices. For each 
measured tissue slice, 15–20 force maps (4 × 4) were 
acquired from randomly chosen areas over the whole tis-
sue section. Thus, for a given human sample, measure-
ments were repeated twice, which resulted in 480–640 
recorded curves. The Young’s modulus calculations 
were performed as previously described for murine 
muscles [17]. Briefly, the force-versus-indentation curves 
were determined by subtracting the calibration curve 
(recorded on a glass coverslip) from the curve recorded 
for the studied muscle sample. To this curve, the Hertz 
model was fit by assuming the conical shape of the 
probing tip. The fit was performed using the proprietary 
code ‘Force’ developed at the Institute of Nuclear Phys-
ics PAN, Kraków, Poland. In this program, the contact 
point is defined as the point where the deflection of the 
cantilever is higher than the level of the base line in force 
curve, as determined manually. The resulting individual 
Young’s moduli were used to calculate the final modu-
lus values. Final Young’s modulus values were obtained 
by averaging the Young’s modulus measurements, as 
obtained from individual muscle fibers pertaining to a 
given muscle type and biopsy storage condition. Statisti-
cal evaluation was performed on individual indentation 
measurements using the unpaired student’s t-test with 
unequal variance, and where applicable, mean values 
and standard errors are shown. Table 1 & Figures 1 & 2 
display mean values plus the standard deviation.
Cytochalasin D treatment of muscle biopsies
Muscle slices as prepared for AFM measurement were 
incubated in DMEM supplemented with 0.1125 µm 
cytochalasin D at 37°C for 30 min. Afterwards, slices 
were rinsed in 1 ml DMEM before AFM  measurement.
Histology
Dystrophin staining was performed on 10–12 µm fro-
zen sections that were incubated with antidystrophin 
antibodies (NCL-Dysl, diluted 1:2; Novocastra–Leica 
Microsystems, Wetzlar, Germany) overnight at 4°C. 
Afterwards, sections were incubated for 35 min at 
room temperature with an antimouse secondary anti-
body conjugated with a horseradish peroxidase-labelled 
polymer (EnVision®+ System, Dako, Baar, Switzer-
land). Subsequently, sections were incubated for 3 min 
with 3,3’-diaminobenzidine (EnVision+ System), so as 
to provide a brown color to dystrophin at muscle fiber 
membranes. Finally, sections were counterstained with 
Mayer’s hematoxylin and eosin, and they were mounted 
with Eukitt (Sigma-Aldrich, MO, USA), so as to stain 
muscle fiber nuclei in light blue and the cytoplasm in 
light pink, in order to reveal the muscle fibers.
Results
Establishment of an AFM assay of human 
muscle biopsies
Earlier AFM studies had suggested that elasticity-based 
nanoindentation assays are capable of detecting changes 
in the stiffness of myofibers’ sarcolemmal membranes, 
as elicited by the presence or absence of dystrophin in 
freshly isolated mouse TA muscles [17]. Here, the authors 
first sought to investigate the feasibility of applying 
AFM to previously frozen clinical muscle biopsies, as 
may be obtained from human patients. The authors 
first assessed gluteus maximus muscle biopsies that 
were obtained from healthy human donors, where part 
of the bio psy was used fresh, while other portions were 
submitted to a prior freezing procedure. Samples were 
then thawed and sectioned longitudinally to preserve 
myo fiber integrity to yield sections with a thickness cor-
responding to approximately ten myofibers (Figure 1A). 
These slices were laid and immobilized on a solid sup-
port to perform nanoindentation AFM assays, and the 
Young’s modulus values representing the muscle fiber 
resistance to elastic deformations were determined, as 
described earlier [17]. 
The mechanical resistance of fresh muscles var-
ied from 7 to 16 kPa for distinct healthy humans 
(Supplementary Figure S1; see online at www.future-
medicine.com/doi/suppl/10.2217/nnm.12.215), and 
thus variability was larger than that determined pre-
viously with fresh muscles from the inbred, and thus 
genetically homogeneous, C57Bl/6j mice [17]. Differ-
ences in human muscle resistance values could not be 
strictly correlated with age or gender of the human 
volunteers. The muscle biopsy portions that had been 
frozen in cooled isopentane were well preserved, as 
they yielded Young’s modulus histograms that were 
nearly identical to those obtained from freshly mea-
sured muscles (Figures 1B & 1C vs 1F & 1G). Some of 
the Young’s modulus values were somewhat lower 
after freezing by direct immersion in liquid nitrogen 
(Figures 1D & 1E). However, these samples appeared 
to be sufficiently well preserved for AFM analysis as 
they yielded average Young’s modulus values that were 
within a normal range of variability, as obtained from 
fresh muscle biopsies from seven healthy individuals 
(Figure 1H & Supplementary Figure S1). 
When assessed similarly, TA muscles from 
healthy mice yielded comparable AFM profiles 
when comparing fresh and frozen mouse muscles 
(Supple mentary Figures S2A & S2B). Frozen muscles from 
dystrophic (mdx) mice yielded lower Young’s modulus 
values (Supplementary Figure S2D), as reported previ-
www.futuremedicine.com 397future science group
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ously from fresh murine muscles [17], confirming that 
accurate AFM profiles can be obtained from frozen mus-
cle explants. Interestingly, the bulk of healthy murine 
myofibers yielded Young’s modulus values in a 2–15 kPa 
range, whereas a minority of more resistant fibers was 
also observed, potentially reflecting different fiber types 
(Supplementary Figures S2A & S2B). This contrasted the 
relatively stiffer and more homogeneous 10–25 kPa range 
observed for fresh biopsies from aged healthy humans 
(Figures 1B & 1C). 
AFM assays of muscles from DMD patients
The authors next proceeded to determine whether 
frozen biopsies from dystrophic patients could be dis-
tinguished from those of healthy individuals. To this 
end, liquid nitrogen-cooled isopentane frozen paraver-
tebral muscle biopsies from DMD and healthy boys 
were assessed by AFM and the Young’s modulus val-
ues were recorded (see Table 1 for all values). Assays 
of paravertebral muscle biopsies from healthy boys 
yielded a range of Young’s modulus values that were 
indicative of resistant muscles (Figures 3A & 3B), while 
DMD human muscle fibers had much lower resis-
tance to de formation (Figures 3C–3E). Muscles from 
DMD patients displayed significantly lower average 
resistance values than those of healthy young sub-
jects (1.10 ± 0.04 kPa vs 3.50 ± 0.10 kPa, respectively; 
p = 3.6 × 10-73), underlining the discriminative reso-
lution of AFM. Representative immuno histological 
staining of muscle biopsies is shown for a healthy and 
DMD patient in Figures 3F & 3G, respectively, con-
firming the lack of dystrophin in the diseased mus-
cle. Interestingly, the Young’s modulus values deter-
mined for healthy boys were rather heterogeneous 
(Figures 3A & 3B), with at least two populations of 
muscle resistance fractions, as obtained from young 
healthy mice (Supplementary Figure S2B). Further-
more, muscles from young humans and mice displayed 
quite similar elasticity values. This contrasted with 
the more homogenous profile and on average stiffer 
properties yielded by muscles of older healthy patients 
(Figures 1B & 1C). The difference correlates with age 
rather than with muscle function or species, as healthy 
human gluteus maximus and healthy murine TA are 
both leg-associated muscles that contribute to posture 
maintenance, but they yielded distinctive homoge-
neous or heterogeneous profiles depending on the 
donor age. 
Although the absolute Young’s modulus values 
can differ when comparing young and aged healthy 
humans, resistance values were similarly very low 
and yielded comparable homogeneous profiles when 
assessing dystrophic muscles from human or murine 
origin (Figure 2 & Supplementary figure S2B), pro-
viding a unambiguous AFM profile for the dystro-
phic muscles. These results taken together imply 
that the AFM assay of muscle function may be per-
formed on frozen human muscle biopsies, and that 
it may provide a  clinically significant evaluation of 
dystrophinopathies.
AFM values of biopsies representing various 
muscle disorders
To further assess whether AFM may provide a func-
tional evaluation of human muscles, biopsies from 
patients affected by other types of dystrophies that 
result from mutations in various components of the 
dystroglycan complex were next investigated. BMD is 
a dystrophinopathy caused by a truncated but partly 
functional dystrophin protein, yielding a milder mus-
cle dysfunction than DMD and at a later age. The 
fukutin-related protein mutated in limb-girdle MD 
(LGMD)2I may control the glycosylation status of 
dystroglycan, ensuring its association to proteins of 
the extracellular matrix in healthy subjects [18]. The 
authors therefore hypothesized that both types of 
mutations may affect the stability of the dystrogly-
can complex and/or its ability to link the extracel-
lular matrix with the cytoskeleton, thereby leading to 
MD in vivo and possibly also to an altered AFM assay 
profile. 
Biopsies from BMD patients yielded low mechani-
cal resistance when compared with a healthy male 
(Figures 2A & 2B). The Young’s modulus values of the 
BMD patients did not depend on age, as abnormally 
low values were noted for both a middle-aged and older 
patient (Table 1). Furthermore, the resistance values of 
BMD muscles, although very low, were not as low as 
those obtained from muscles from patients affected by 
DMD (1.40 ± 0.001 kPa vs 2.90 ± 0.006 kPa, respec-
tively; p = 8.3 × 10-36), thus correlating well with the 
more severe muscle dysfunction associated to the latter 
disease. Furthermore, the 37-year-old patient with the 
earlier onset and more severe form of BMD had a lower 
Young’s modulus value than the 50-year-old BMD 
patient, indicating that the elasticity value relates to 
the severity of these dystrophinopathies. This find-
ing was further confirmed by AFM of a biopsy from 
a rare female manifesting the DMD carrier [19]. Its 
biopsy yielded a mean Young’s modulus value that was 
higher than those found in BMD males, but below the 
range found for healthy subjects, further supporting 
the conclusion that myofiber elasticity correlates with 
 dystrophin function in humans. 
Likewise, the biopsy from a LGMD2I female patient 
showed anomalously low Young’s modulus values com-
pared with a healthy female (Figures 2C & 2D). This 
paralleled an assay performed on a murine model for 
www.futuremedicine.com 401future science group
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Figure 2. Muscle biopsies from Becker muscle dystrophy and limb-girdle muscular dystrophy type 2I patients and mice models yield a 
dystrophic atomic force microscopy assay profile. Human biopsies previously frozen in liquid nitrogen were thawed and processed for the 
atomic force microscopy assays alongside freshly explanted mouse muscle. Young’s modulus elasticity profiles are shown for biopsies of a (A) 
gluteus maximus muscle of a 68-year-old healthy human male subject; (B) a deltoid muscle from a 37-year-old male Becker muscle dystrophy 
patient; (C) a healthy gluteus maximus muscle taken from a 78-year-old female human subject and for a (D) vastus lateralis muscle from a 
31-year-old female limb-girdle muscular dystrophy type 2I patient. Young’s modulus profiles were also determined on a (E) tibialis anterior 
muscle from a healthy mouse control aged 5 weeks and from a (F) tibialis anterior muscle obtained from a FKRP knock-out mouse as a model 
of limb-girdle muscular dystrophy type 2I, also 5 weeks old and from the same littermate as the animal analyzed in (E).  
E: Young’s modulus value.
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LGMD2I bearing a homozygous knock-in of a human 
mutation in the gene encoding the fukutin-related pro-
tein (Figures 2E & 2F) and those obtained from a human 
patient affected by a LGMD2B muscle disease (Table 1). 
Again, the Young’s modulus values were low, but not as 
low as those from patients affected by the more severe 
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Figure 3. Duchenne muscular dystrophy biopsies have a distinctly low resistance to deformation. Paravertebral muscle biopsies of 
0.5 cm3, previously frozen in liquid nitrogen-cooled isopentane, were thawed and processed for atomic force microscopy assays. 
(A) Healthy male aged 16 years. (B) Healthy male aged 11 years. (C) Duchenne muscular dystrophy male aged 14 years. (D) Duchenne 
muscular dystrophy male aged 14 years. (E) Duchenne muscular dystrophy male aged 15 years. Dystrophin immunohistological 
staining was performed on sections of the muscles of a (F) healthy and (G) dystrophic patient. 
E: Young’s modulus value.
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DMD, indicating again that the AFM-determined 
resistance values may provide a  quantitative assessment 
of the severity of muscle  dysfunction. 
To strengthen this conclusion, the authors next 
expanded their study to a larger collection of available 
frozen human muscle biopsies. Overall, muscles from 
patients affected by 11 diseases were probed (Table 1). All 
assayed muscles from patients with dystrophinopathies 
had extremely low mechanical resistance, with no fiber 
having normal or near-normal AFM-assessed elasticity 
values. Patients of various ages and genders affected by 
various other types of muscle disorders with weakness, 
including polymyositis, hereditary inclusion body myo-
sitis, Ulrich congenital MD and myofibrillar myopathy, 
all yielded various degrees of abnormal muscle resistance 
as detected by the AFM assay (Table 1). 
Having determined that muscle dysfunction asso-
ciated with a variety of previously diagnosed muscle 
diseases can be detected by the AFM assay, the authors 
turned to muscle diseases where diagnosis may be 
more difficult. For instance, the authors assessed a 
family affected by a novel type of nemaline myopathy 
for which no molecular or genetic marker is known, 
whereas histology or other available assays do not 
allow unambiguous diagnosis [20]. Most, if not all, of 
the family members appear to be affected by a mild 
but variable muscle weakness, which is difficult to 
diagnose as muscle performance can be also affected 
by the lifestyle and training particular to each indi-
vidual. Distinct family members yielded different 
AFM profiles, with some individuals yielding AFM 
profiles close to those of BMD patients, whereas oth-
ers yielded normal or near-normal muscle resistance 
(see Supplementary Figures S3A & S3B for representative 
AFM profiles). Older family members had muscles of 
significantly lower resistance (3.90 ± 0.01 kPa vs 7.70 
± 0.01 kPa; p = 5.0 × 10-59, when comparing indi-
viduals older or younger than 50 years, respectively), 
while gender or fiber-type composition did not affect 
the AFM Young’s modulus values (Table 1 and data 
not shown). Interestingly, incubation of the nemaline 
myopathy biopsy sections with cyto chalasin D revealed 
fibers that were resistant to the softening induced by 
this treatment (Supplementary Figure S4). This indi-
cated that a portion of the fibers had a stiff behavior 
that was independent of the cytoskeleton integrity, 
potentially reflecting the presence of proteinaceous 
aggregates, as seen by microscopy in some patients. In 
addition, the heterogeneity seen in the AFM profiles 
from different affected nemaline myopathy family 
members was also found in sporadic inclusion body 
myositis (Supplementary Figures S3C & S3D), possibly 
reflecting similar molecular depositions. 
Finally, the authors also assessed two patients who 
were consulting for suspected muscle weakness but 
were classified as healthy, as muscle biopsy histology 
did not reveal abnormal structures and no known 
muscle disease diagnostic marker was found. For 
one of the two patients, a 30-year-old male, a low 
Young’s modulus value was found, similarly to what 
was encountered in patients displaying known MDs 
(Supplementary Figure S5). Overall, the authors con-
clude that probing muscle biopsies by AFM indenta-
tion at the nanometric scale may be capable of revealing 
mild muscular defects, and this even in the absence of 
fully developed or otherwise detectable symptoms.
Discussion & conclusion
This study reports a first in situ functional assessment of 
a variety of human muscle fibers by AFM. When com-
paring fresh human muscle samples with frozen biop-
sies obtained from clinical collections, we concluded 
that valid measurements can be obtained from biopsies 
as routinely processed and stored at hospitals, and that 
this approach can be applied to distinguish healthy 
from diseased human muscles. Both the Young’s mod-
ulus histogram profile and the mean modulus value are 
well preserved in frozen tissues, whether from human 
or mice origin. Although several freezing methods were 
found to be applicable, we recommend using biopsies 
frozen in liquid nitrogen-cooled isopentane for future 
AFM studies of human muscles, as this approach did 
not alter myofiber resistance to any detectable extent. 
We previously reported that mdx mice lacking dystro-
phin have low resistance myofibers compared with those 
of healthy mice, and that dystrophin expression by a gene 
therapy approach did restore a normal AFM profile from 
the animal dystrophy model [17]. This suggested that the 
dystrophin-mediated attachment of the sarco lemmal 
membrane to the underlying actin cytoskeleton was pro-
viding resistance to the mechanical indentation induced 
by the AFM cantilever pressure. This report shows that 
fibers of abnormally low resistance occur more gener-
ally in conjunction with various other muscle diseases, 
as characterized by a number of distinct molecular or 
cellular defects. These ranged from the disjunction of 
the dystroglycan complex connection to the myofiber’s 
actin cytoskeleton, as in DMD or BMD patients, or to 
the extracellular matrix as in fukutin-related protein, to 
muscle diseases associated to an immune and inflamma-
tory response of the muscle tissues, as in polymyositis. 
All of these disease share the common feature of muscle 
strength loss. The extent of muscle strength loss associ-
ated with particular diseases correlated well with the loss 
of muscle resistance to elastic deformation, as probed 
by AFM. This correlation is further supported by the 
comparison of biopsies from patients affected by simi-
lar diseases, but with a different severity. For instance, 
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DMD patients who fully lack dystrophin have lower 
Young’s modulus values than those obtained from the 
BMD patients assessed in this study that express abnor-
mally low but detectable levels of full-length dystrophin 
(Table 1). Furthermore, the 37-year-old BMD patient 
showed a dystrophic AFM profile that was more severe 
than the profile of the BMD patient aged 50 years, 
which correlated well with the earlier and more severe 
phenotype of the 37-year-old patient. A number of other 
muscle diseases that have later disease onset and/or sever-
ity consistently yielded AFM values that were between 
those of the most severely affected DMD patients and 
those obtained from healthy volunteers. We therefore 
conclude that use of the AFM assay is not limited to the 
detection of diseases that affect the sarcolemmal mem-
brane resistance to elastic deformation, but that it probes 
a more generally relevant  biophysical property of the 
muscle that underlies strength.
The AFM indentation assay probes the resistance 
of inner cellular structures at a nanometric scale, as 
defined by the depth at which the pressure required 
to indent the membrane is recorded [17]. In this study, 
this was assessed at a depth of approximately 500 nm 
after the initial contact point between the approach-
ing cantilever tip and the myofiber surface. As this 
depth extends beyond the 10 nm sarcolemma and 
150 nm dystrophin link, the sarcolemmal membrane 
is pushed further within the myofiber until it reaches 
a more resistant inner structure, deeper than the actin 
microfilaments directly underlying the sarcolemma. 
In some cases, the cantilever might probe rigid struc-
tures that result from particular muscle pathological 
processes. For instance, in the sporadic inclusion body 
myositis, particular patients can show rod-shaped 
proteinaceous structures deposited within some of 
the myofibers. Interestingly, heterogeneous resistance 
values were observed in the myofibers of one such 
female subject, where some fiber locations were found 
to correspond to stiffer structures than those of the 
surrounding fibers in the biopsy, or those from healthy 
subject fibers.
Alternatively, the inner structures probed by the can-
tilever might be the contractile apparatus that mediates 
muscle strength. This interpretation is supported by the 
correlation of muscle strength loss, as elicited by the vari-
ous diseases assessed, with the Young’s modulus value 
that was determined from the myofibers. Thus, the abil-
ity of the probed cellular structures to resist deformation, 
as exerted by the cantilever tip pressure, might be directly 
correlated to the functional resistance of the sarcomeric 
contractile unit. In future studies, it will be interesting 
to assess this possibility further by probing muscles with 
impaired components of the sarcomeric structure, such 
as muscles lacking titin, the protein that acts as a molecu-
lar spring that connects sarcomeres to provide the passive 
elasticity of the muscle. While the main aim of this study 
was to establish the elastic properties of tissue sections as 
a potential diagnostic nanometric marker, another inter-
esting perspective will be to perform AFM-based imag-
ing to determine if various types of diseases may be dis-
tinguished on the basis of possibly distinct morphologi-
cal changes. In any case, although the precise structure 
probed by AFM remains to be identified, we conclude 
that the AFM-mediated nano indentation assay may be 
capable of probing muscle function, as affected by a wide 
range of disease associated with muscle weakness.
Interestingly, we detected very soft fibers in one 
consulting patient rated as having an undiagnosed 
muscle condition, as no objective criterion justifying a 
muscle disease diagnosis could be identified by other 
assays, including skeletal muscle strength, enzyme lev-
els, electrodiagnostic study, muscle imaging and his-
tology, which were all found to be within the normal 
variation limits. The abnormal AFM profile may thus 
point to an underlying muscle disease not diagnosed 
as yet by other approaches. Biopsies from the members 
of a family affected by another muscle condition that 
is difficult to diagnose by conventional means, hav-
ing a mild form of atypical nemalin myopathy, were 
also found to contain soft fibers, although in varying 
proportions. Thus, AFM may provide a useful addi-
tional approach to diagnose MDs, even in the absence 
of a severe phenotype or of a known molecular disease 
mechanism. Overall, we conclude that AFM shows 
promise as an additional diagnostic tool in routine 
clinical use and possibly also to evaluate clinical trial 
outcome. 
Future perspective
We speculate that AFM will be increasingly applied to 
the preclinical and clinical evaluation of muscle thera-
pies owing to its high sensitivity and ability to give a 
functional read-out from single fibers embedded within 
the muscular tissue. The high-resolution data that can 
be generated by this novel approach may also aid in the 
optimization of gene therapy vector dosage, administra-
tion route and regimen, by improving the outcome of 
preclinical and clinical trials. In the long-term, AFM 
may become a standard diagnosis tool for myo pathies, 
facilitating the selection of the most effective clinical 
treatment strategy.
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Executive summary
Aim
•	 The authors wished to assess whether atomic force microscopy can be used to probe the elastic properties of 
human myofibers from live or frozen tissues in situ. 
Results
•	 This study demonstrates the feasibility of assessing various human muscular dystrophies at the nanometer 
scale, as based on atomic force microscopy assays of frozen human clinical biopsies.
•	 Biopsies from dystrophic patients all showed presence of myofibers with abnormally low mechanical resistance 
to deformation, even for very mild dystrophies that are difficult to diagnose unambiguously from muscle 
strength or other assays.
•	 One consulting patient with normal muscle histology and circulating muscle markers but with cardiac arrhythmia 
also showed soft myofibers, implying occurrence of a muscular dystrophy undetectable by other assays.
Conclusion
•	 Myofiber elasticity, described quantitatively by the Young’s modulus, may thus be useful in the diagnosis of 
muscular dystrophies with uncharacterized or otherwise undetectable molecular or cellular defects.
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